| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/18/2002 | CA2431566A1 Topical testosterone formulations and associated methods |
| 07/18/2002 | CA2430794A1 Human genes and gene expression products isolated from human prostate |
| 07/18/2002 | CA2430060A1 Diagnostic tumor markers, drug screening for tumorigenesis inhibition, and compositions and methods for treatment of cancer |
| 07/18/2002 | CA2429177A1 Inhibition of nf-.kappa.b by triterpene compositions |
| 07/18/2002 | CA2428497A1 Targeted modification of intracellular compounds |
| 07/18/2002 | CA2428075A1 Fumaric acid derivatives as nf-kappab inhibitors |
| 07/18/2002 | CA2427840A1 Methods of using imxp-888 and imxp-888 antagonists |
| 07/18/2002 | CA2425625A1 Aza-and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
| 07/18/2002 | CA2403617A1 Agent for prevention or treatment of allergosis, and medical aqueous agent, ophthalmic solution and nasal drop for allergosis |
| 07/18/2002 | CA2395711A1 Pharmaceutical compositions |
| 07/17/2002 | EP1223176A2 Peptide mutant of human ERAB/HADH2, its X-ray crystal structure, and materials and method for identification of inhibitors thereof |
| 07/17/2002 | EP1223173A2 Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof |
| 07/17/2002 | EP1223166A1 Linked cyclic polyamines with activity against hiv. |
| 07/17/2002 | EP1222931A1 Percutaneous absorption promoters for electroporation |
| 07/17/2002 | EP1222927A2 Pharmaceutical compositions having appetite suppressant activity |
| 07/17/2002 | EP1222926A1 Cationic polysaccharide compositions |
| 07/17/2002 | EP1222925A2 Kavalactone as TNF-alpha production inhibitor |
| 07/17/2002 | EP1222924A1 Anticancer agents |
| 07/17/2002 | EP1222923A1 Nicotine transdermal delivery composition for smoking cessation |
| 07/17/2002 | EP1222922A1 Method for stabilizing benzimidazole compounds |
| 07/17/2002 | EP1222921A1 Pharmaceutical compositions of tizoxanide and nitazoxanide |
| 07/17/2002 | EP1222920A2 Mitochondria protecting agents for treating mitochondria associated diseases |
| 07/17/2002 | EP1222919A2 Compositions comprising glycoprotein matrix and active compound and methods for manufacture thereof |
| 07/17/2002 | EP1222918A1 Microcapsules for stabilizing cosmetic, pharmaceutical or food products |
| 07/17/2002 | EP1222463A2 Allosteric sites on muscarinic receptors |
| 07/17/2002 | EP1222313A2 Genes associated with obesity and methods for using the same |
| 07/17/2002 | EP1222308A1 Antiprotozoal histone acetyl transferase inhibitors |
| 07/17/2002 | EP1222302A1 Process for producing, methods and compositions of cholesterol lowering agents from higher basidiomycetes mushrooms |
| 07/17/2002 | EP1222286A2 Aortic carboxypeptidase-like protein and nucleic acids encoding same |
| 07/17/2002 | EP1222284A2 22196, a novel human aminopeptidase |
| 07/17/2002 | EP1222279A2 Growth factor polypeptides and nucleic acids encoding same |
| 07/17/2002 | EP1222277A2 Endozepine-like polypeptides and polynucleotides encoding same |
| 07/17/2002 | EP1222273A2 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 07/17/2002 | EP1222266A2 Pca3 messenger rna species in benign and malignant prostate tissues |
| 07/17/2002 | EP1222265A1 Novel nicotinic acetylcholine receptor subunit, its isolation and use |
| 07/17/2002 | EP1222260A1 Preparation of cellular components that are substantially free of chromosomal dna |
| 07/17/2002 | EP1222259A1 ALTERING GENE EXPRESSION WITH ssDNA PRODUCED IN VIVO |
| 07/17/2002 | EP1222211A1 Pcna associated cell cycle proteins, compositions and methods of use |
| 07/17/2002 | EP1222209A2 Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
| 07/17/2002 | EP1222203A1 Method of altering polypeptide aggregation |
| 07/17/2002 | EP1222195A1 Novel thiazolo(4,5-d)pyrimidine compounds |
| 07/17/2002 | EP1222194A1 7-acylamino-3-heteroarylthio-3-cephem carboxylic acid antibiotics and prodrugs thereof |
| 07/17/2002 | EP1222193A2 Imidazole derivatives as phosphodiesterase vii inhibitors |
| 07/17/2002 | EP1222192A1 Hexahydrofuro[2,3-b]furan-3-yl-n- 3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl carbamate as retroviral protease inhibitor |
| 07/17/2002 | EP1222191A2 Benzodiazepin derivatives, the production and use thereof |
| 07/17/2002 | EP1222190A1 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors |
| 07/17/2002 | EP1222188A1 Novel imidazopyridine carbonitrile compounds |
| 07/17/2002 | EP1222187A2 Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| 07/17/2002 | EP1222186A2 Condensed naphthyridines as hiv reverse transcriptase inhibitors |
| 07/17/2002 | EP1222185A1 Tetrahydrobenzindolone derivatives, their preparation and their use as 5-ht7 receptor antagonists |
| 07/17/2002 | EP1222183A1 Benzopyran derivatives |
| 07/17/2002 | EP1222182A2 Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benozopyrans |
| 07/17/2002 | EP1222180A2 Enantiomeric compounds for treatment of cardiac arrhythmias and methods of use |
| 07/17/2002 | EP1222175A1 4,5-disubstituted-2-aminopyrimidines |
| 07/17/2002 | EP1222171A1 Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof |
| 07/17/2002 | EP1222170A1 Novel nicotinonitrile compounds |
| 07/17/2002 | EP1222169A1 Novel trisubstituted pyridine compounds |
| 07/17/2002 | EP1222163A1 2'-substituted 1,1'-biphenyl-2-carbonamides, method for the production thereof, use thereof as a medicament and pharmaceutical preparations containing said compounds |
| 07/17/2002 | EP1222162A1 Novel ltb 4? antagonist, method for the production thereof and its use as a medicament |
| 07/17/2002 | EP1222158A1 Radical scavenger |
| 07/17/2002 | EP1221997A1 System and device for preventing restenosis in body vessels |
| 07/17/2002 | EP1221982A1 Isoalloxazine derivatives to neutralize biological contaminants |
| 07/17/2002 | EP1221981A1 Method and apparatus for producing a sterile fluid |
| 07/17/2002 | EP1221977A2 Tumor detection by imaging and therapy of tumors |
| 07/17/2002 | EP1221975A2 Polymer stabilized neuropeptides |
| 07/17/2002 | EP1221974A2 Magnetic targeted carrier |
| 07/17/2002 | EP1221962A2 Inhibitors of proteasomal activity for stimulating bone and hair growth |
| 07/17/2002 | EP1221957A2 Method for preparing a composition by mother-of-pearl extraction,and use thereof in cosmetics and dermatology |
| 07/17/2002 | EP1221955A2 Immunostimulatory nucleic acids |
| 07/17/2002 | EP1221953A1 Treating sleep disorders using desloratadine |
| 07/17/2002 | EP1221952A1 Use of central cannabinoid receptor antagonist for preparing medicines |
| 07/17/2002 | EP1221951A1 Treatment of pancreatic disease |
| 07/17/2002 | EP1221950A1 Synergistic combinations of an nk 1? receptor antagonist and a gaba structural analog |
| 07/17/2002 | EP1221949A2 Method and composition for prophylaxis and treatment of symptoms associated with cold and influenza-like illnesses |
| 07/17/2002 | EP1221947A2 Soft gel capsule resistant to gastric juices |
| 07/17/2002 | EP1221945A1 Methods, pharmaceutical and therapeutic compositions for administering adenosine |
| 07/17/2002 | EP1221944A1 Oral dosage form comprising a salt of morphine or a morphine derivative |
| 07/17/2002 | EP1221941A1 Powder pharmaceutical formulations |
| 07/17/2002 | EP1221940A2 Liposome formulation of 6,9-bis- (2-aminoethyl)-amino]benzo g]isoquinoline-5,10-dione dimaleate |
| 07/17/2002 | EP1221939A1 Ortho ester lipids |
| 07/17/2002 | EP1221938A2 Method for producing liposome preparation |
| 07/17/2002 | EP1221937A2 Hybrid matrices and hybrid matrix mixtures |
| 07/17/2002 | EP1221934A1 Antimicrobial perfuming compositions |
| 07/17/2002 | EP1221933A2 Composition, especially a cosmetic composition, containing a steroid and a liposoluble uv filter |
| 07/17/2002 | EP1221926A1 Pharmaceutical formulations containing poorly soluble drug substances |
| 07/17/2002 | EP1221917A1 Drug delivery device |
| 07/17/2002 | EP1221908A1 Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| 07/17/2002 | EP1221868A1 Dietary supplement |
| 07/17/2002 | EP1221867A1 Nutritional composition |
| 07/17/2002 | EP1221865A2 Food supplement for increasing lean mass and strength |
| 07/17/2002 | EP1221861A1 Fat or oil composition |
| 07/17/2002 | EP1221852A2 Antimicrobial compositions comprising a benzoic acid analog and a metal salt |
| 07/17/2002 | EP1221851A2 Antiviral compositions for tissue paper |
| 07/17/2002 | EP1221847A1 Methods of enhancing chemotherapy |
| 07/17/2002 | EP1221845A1 Active ingredient combinations having insecticidal and acaricidal properties |
| 07/17/2002 | EP1123104A4 Inherently antimicrobial quaternary amine hydrogel wound dressings |
| 07/17/2002 | EP1105002B1 Carbohydrates mixture |
| 07/17/2002 | EP1083900B1 Use of of oxazolidinones for the preparation of a medicament for transdermal delivery |
| 07/17/2002 | EP1073440A4 sPLA 2 INHIBITOR ESTER |
| 07/17/2002 | EP1066293B1 New porphyrins and their use |